Indian Pharma Companies

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Wockhardt gains 4% on filing for DCGI's approval for its insulin injection

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Lyka Labs shares rally 7% on CDSCO nod for diabetic neuropathy pain drug

Lyka Labs shares rose as the company announced that it has received the CDSCO approval for manufacturing & marketing of of Pregabalin Gel 8% w/w for use in patients with Diabetic Neuropathic Pain.

Indian pharma market registers over 5% growth in Sept 2024: Pharmarack

This comes even as the IPM registered a negative unit growth of -2.3 per cent, with only anti-diabetic and urology therapy segments recording significant unit growth of 3.1 per cent and 5.4 per cent

Indian pharma companies set to see 9-11% growth in FY25, says Icra

The domestic market is expected to see a positive turnaround, with ICRA projecting revenue growth of 7-9 per cent for its sample set of companies in FY25

Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.

SeQuent Scientific jumps 18% after announcing merger with Viyash Life

The company said the proposed merger is expected to be Ebitda margin accretive and deleverage SeQuent's balance sheet.fle

Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings

The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit profiles, even as pharma cos pursue acquisitions in niche therapeutic areas

Granules tanks 16% on concerns over 6 observations issued by US FDA

More than 31 million equity shares, representing 12.89 per cent equity of the pharmaceutical company, had changed hands on the NSE till 02:08 PM.

Pharma's bitter pill: Falling API prices signal Chinese predatory play

An industry expert pointed out that Chinese companies typically resort to predatory pricing whenever API production increases in India

Akums Drugs strengthens global presence with European market expansion

The decision to enter the European market comes at a time when the global pharmaceutical landscape is undergoing changes

Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24

Dr Reddy's Lab pushes the pedal to touch 1.5 billion patients by FY30

The company also announced that it will work together with the United States Food and Drug Administration (USFDA) to launch the biosimilar rituximab in the US

AstraZeneca to invest Rs 250 crore in expanding its GITC in Chennai

This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai

USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility

Sun Pharma failed to adequately clean and maintain equipment used for drug manufacturing at its Dadra-based manufacturing plant, as per the US Food and Drug Administration (USFDA). In a warning letter issued to company's Managing Director Dilip Shanghvi on June 18, the US health regulator stated it inspected the plant in the Union Territory of Dadra and Nagar Haveli and Daman and Diu from December 4-15, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said. The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility, it stated. USFDA further noted that the company's investigations

Indian pharma sites outpace global standards in USFDA inspections for 2023

The USFDA categorised 13 per cent (19 out of 145 inspections) of Indian facilities as 'Official Action Indication'(OAI), which is lower than the global average of 15 per cent OAIs

Major fire engulfs garment, pharma factories in Noida, no casualty reported

A fire ripped through a garment factory here and spread to an adjoining pharmaceutical factory, prompting a major relief operation that lasted for more than eight hours and utilised services of over two dozen water tenders, officials said on Saturday. Chief Fire Officer (CFO) Pradeep Kumar said no one was injured in the incident that took place in B-Block of Sector 67. The fire service unit's control room received an alert call about the fire at 12 noon, he said. "We immediately sent eight vehicles to the spot but found that it was a major fire, which had spread from the garment factory to the adjoining pharmaceutical factory. This pharma factory was shut for the past two years but the items which were stocked inside caught the fire and intensified the blaze," Kumar said. "We had to deploy 28 vehicles and by 8.30 pm we were able to completely extinguish the fire. Fortunately, there was no injury to any person and no loss of life in the incident," the CFO said. Kumar said additiona

Pharmaceutical companies prepare to comply with ethical marketing code

Companies must commit that they comply with a code against unethical marketing of drugs

Cipla rallies 4% on US FDA approval to market Lanreotide injection

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

Pharma major Glenmark gets USFDA nod for generic ophthalmic solution

Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions. The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement. The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2 per cent/0.5 per cent has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2 per cent/0.5 per cent of AbbVie, Inc, it added. The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added. Combigan ophthalmic solution, 0.2 per cent/0.5 per cent achieved annual sales of approximately USD 290 million, the company said citing IQVIATM sales data